Study of Dovramilast for Leprosy Type 2 Reaction
Treatments studied
Part of Infections clinical trials.
This study tests a new medicine called dovramilast for people with leprosy type 2 reaction, a painful inflammatory condition that can cause skin bumps and nerve problems. It compares the study drug to standard care to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have or had leprosy, confirmed by a lab test.
- You are having a leprosy type 2 reaction that is either new (first episode) or has come back at least 28 days after stopping treatment.
- You have at least 10 tender, red bumps or nodules on your skin from this reaction, and a score of 9 or more on the ENLIST scale.
- If you are a woman of childbearing age, you must agree to use two reliable birth control methods (including one highly effective method) from screening until 4 weeks after treatment ends.
- If you are a man, you must agree to use a latex condom during any sexual contact with a woman of childbearing age from screening until 4 weeks after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine (LEP-F1 + GLA-SE) to see if it is safe and helps the body fight leprosy. It is for healthy adults living in areas where leprosy is common.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
This study looks at whether a specific gene (Rab 32) affects how leprosy progresses. It may help doctors better predict outcomes for people with leprosy.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
This study tests two new oral medicines compared to an existing oral medicine for people with a first episode of cutaneous leishmaniasis (skin sores caused by a parasite). It aims to find a more effective and convenient treatment.
This trial tests a cream (ruxolitinib) on discoid lupus skin lesions. It aims to see if the cream can reduce DLE symptoms in adults.
Hear when a new Erythema Nodosum Leprosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.